# Linerixibat Long-term Safety, and Tolerability Study

> **NCT04167358** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 242 (actual)

## Conditions studied

- Cholestasis

## Interventions

- **DRUG:** Linerixibat

## Key facts

- **NCT ID:** NCT04167358
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-14
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167358, "Linerixibat Long-term Safety, and Tolerability Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04167358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*